[go: up one dir, main page]

FI961350A0 - Hapteenimerkityt peptidit - Google Patents

Hapteenimerkityt peptidit

Info

Publication number
FI961350A0
FI961350A0 FI961350A FI961350A FI961350A0 FI 961350 A0 FI961350 A0 FI 961350A0 FI 961350 A FI961350 A FI 961350A FI 961350 A FI961350 A FI 961350A FI 961350 A0 FI961350 A0 FI 961350A0
Authority
FI
Finland
Prior art keywords
hapten
pct
protecting groups
cleaved
primary amino
Prior art date
Application number
FI961350A
Other languages
English (en)
Swedish (sv)
Other versions
FI961350A7 (fi
FI961350L (fi
Inventor
Eva Hoess
Christoph Seidel
Ursula-Henrike Wienhues
Elke Faatz
Urban Schmitt
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4430973A external-priority patent/DE4430973A1/de
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of FI961350A7 publication Critical patent/FI961350A7/fi
Publication of FI961350A0 publication Critical patent/FI961350A0/fi
Publication of FI961350L publication Critical patent/FI961350L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI961350A 1994-07-25 1995-07-24 Hapteenimerkityt peptidit FI961350L (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4426276 1994-07-25
DE4430973A DE4430973A1 (de) 1994-07-25 1994-08-31 Hapten-markierte Peptide
PCT/EP1995/002921 WO1996003423A1 (de) 1994-07-25 1995-07-24 Hapten-markierte peptide

Publications (3)

Publication Number Publication Date
FI961350A7 FI961350A7 (fi) 1996-03-25
FI961350A0 true FI961350A0 (fi) 1996-03-25
FI961350L FI961350L (fi) 1996-03-25

Family

ID=25938669

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961350A FI961350L (fi) 1994-07-25 1995-07-24 Hapteenimerkityt peptidit

Country Status (13)

Country Link
US (1) US5804371A (fi)
EP (1) EP0723551B1 (fi)
JP (1) JP2921989B2 (fi)
CN (1) CN100478352C (fi)
AT (1) ATE214073T1 (fi)
AU (1) AU684992B2 (fi)
CA (1) CA2172144C (fi)
DE (1) DE59510092D1 (fi)
ES (1) ES2171190T3 (fi)
FI (1) FI961350L (fi)
NO (1) NO316381B1 (fi)
NZ (1) NZ291155A (fi)
WO (1) WO1996003423A1 (fi)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2195753C (en) * 1994-07-25 2008-12-16 Ursula-Henrike Wienhues Determination of a specific immunoglobulin using multiple antigens
WO1998007364A1 (de) * 1996-08-16 1998-02-26 Roche Diagnostics Gmbh Kontrollsystem für die überwachung der regelmässigen einnahme eines medikamentes
DE19649389A1 (de) * 1996-11-29 1998-06-04 Boehringer Mannheim Gmbh Antigenspezifischer IgM-Nachweis
EP0972198B2 (de) 1997-03-10 2013-12-11 Roche Diagnostics GmbH Verfahren zur simultanen bestimmung von hiv-antigenen und hiv-antikörpern
DE19816550A1 (de) 1997-12-24 1999-06-24 Roche Diagnostics Gmbh Universell verwendbarer Aufbau eines Analysenelements und dessen Einsatz zur Analytbestimmung
EP0957360B1 (de) * 1998-05-06 2002-07-31 Roche Diagnostics GmbH Entstörung durch Rheumafaktoren
DE19828466A1 (de) 1998-06-26 1999-12-30 Roche Diagnostics Gmbh Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
US6503736B1 (en) 1999-11-12 2003-01-07 BIOMéRIEUX, INC. Antibodies to crosslinkers and methods for using the same
DE10048417A1 (de) * 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
US7897404B2 (en) 2000-09-29 2011-03-01 Roche Diagnostics Operations, Inc. Conjugates of defined stoichiometry
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP1698636A1 (en) * 2001-05-02 2006-09-06 Novo Nordisk A/S Preparation of derivatized peptides from bile acids
FR2843115B1 (fr) * 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
JP2005172694A (ja) 2003-12-12 2005-06-30 Fuji Photo Film Co Ltd タンパク質の検出方法
DE102005051978A1 (de) * 2005-10-31 2007-05-10 Forschungszentrum Borstel Zentrum für Medizin und Biowissenschaften Verfahren zur Bestimmung der Spaltbarkeit von Substraten
JP4975600B2 (ja) * 2007-03-16 2012-07-11 シスメックス株式会社 Ｈｃｖ抗体測定用試薬キット及びｈｃｖ抗体測定方法
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
BR112013014644A2 (pt) 2011-01-03 2017-03-07 F Hoffmann - La Roche Ag composição farmacêutica e complexo
CN102323409B (zh) * 2011-01-17 2014-03-05 广东海大畜牧兽医研究院有限公司 一种病毒感染检测方法
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
KR102090849B1 (ko) 2012-07-04 2020-03-19 에프. 호프만-라 로슈 아게 공유 결합된 항원-항체 접합체
KR20150030755A (ko) 2012-07-04 2015-03-20 에프. 호프만-라 로슈 아게 항-바이오틴 항체 및 사용 방법
EP2869837B1 (en) 2012-07-04 2016-09-14 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015101587A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
JP6476194B2 (ja) 2014-01-03 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗ハプテン／抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
MX373017B (es) 2014-01-03 2020-04-28 Hoffmann La Roche Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2023242155A1 (en) 2022-06-14 2023-12-21 Janssen Vaccines & Prevention B.V. Compositions and methods for the diagnosis of hiv infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135773B (en) * 1983-01-31 1985-12-04 Boots Celltech Diagnostics Enzyme inhibitor labelled immunoassay
US4767720A (en) * 1985-08-29 1988-08-30 Hsc Research Development Corporation Antidigoxin antibodies
US5087561A (en) * 1990-06-28 1992-02-11 Merck & Co., Inc. Humoral hypercalcemic factor antagonists modified at position 13 by biotin
IL99077A0 (en) * 1990-08-13 1992-07-15 Merck & Co Inc New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them
ES2287969T3 (es) * 1992-03-06 2007-12-16 Innogenetics N.V. Peptidos de vih.
DE4402756A1 (de) * 1994-01-31 1995-08-03 Boehringer Mannheim Gmbh Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine

Also Published As

Publication number Publication date
JP2921989B2 (ja) 1999-07-19
FI961350A7 (fi) 1996-03-25
CN100478352C (zh) 2009-04-15
AU684992B2 (en) 1998-01-08
US5804371A (en) 1998-09-08
NO316381B1 (no) 2004-01-19
WO1996003423A1 (de) 1996-02-08
JPH09500915A (ja) 1997-01-28
ATE214073T1 (de) 2002-03-15
ES2171190T3 (es) 2002-09-01
EP0723551A1 (de) 1996-07-31
NO961162L (no) 1996-03-21
NO961162D0 (no) 1996-03-21
DE59510092D1 (de) 2002-04-11
CN1130910A (zh) 1996-09-11
AU3220695A (en) 1996-02-22
CA2172144C (en) 2001-02-06
EP0723551B1 (de) 2002-03-06
NZ291155A (en) 1997-09-22
FI961350L (fi) 1996-03-25

Similar Documents

Publication Publication Date Title
FI961350A0 (fi) Hapteenimerkityt peptidit
JP2633481B2 (ja) 酵素抵抗性免疫調節ペプチド
AU6172596A (en) Neuroactive steroids of the androstane and pregnane series
US4372884A (en) Pharmaceutically active peptides
DE69030100D1 (de) Peptidderivat, verfahren zu dessen herstellung, sowie dieses enthaltende pharmazeutische zusammensetzung
WO1998043936A3 (en) Improved methods of manufacturing betulinic acid
Parmentier et al. Synthesis and characteristics of the specific monosulfates of chenodeoxycholate, deoxycholate and their taurine or glycine conjugates
ATE205851T1 (de) Neue steroide mit radikophilen substituenten, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0135782A3 (en) New derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
CA1209045A (en) Lhrh preparations for intranasal administration
MX9101382A (es) Analogo de aprotinina,metodo para su produccion y composicion farmaceutica que la contiene
DE69314570D1 (de) Verfahren zur Herstellung Taurin-konjugierter Gallensäure
FI74473B (fi) Foerfarande foer framstaellning av nya, pao det centrala nervsystemet inverkande tripeptidamider.
DE69321177D1 (de) Verfahren zur Herstellung Glycin-konjugierter Gallensäure
CA2258177A1 (en) 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
DK154573C (da) Fremgangsmaade til fremstilling af insuliner ud fra tilsvarende praeproinsulinanaloge
US4107158A (en) Process for making an octapeptide useful for the treatment of diabetes
JPH01500430A (ja) グルココルチコイド的性質及び抗炎症性を有する，含硫アミノ酸又は非含硫アミノ酸と△―４―プレグネン―３，２０―ジオン誘導体又は△―１，４―プレグナジエン―３，２０―ジオン誘導体との結合合成化合物，製造方法，それ等を含む医薬組成物，薬理活性及び使用
CA2158643A1 (en) New glucocorticoids
CA2196690A1 (en) Pregnanes and cholanes as neurochemical initiators of change in hypothalamic function
Schellenberger et al. Specific water-soluble substrates for chymotrypsin: Attempts for compensating diminished P 1-S 1 interactions
GB1532181A (en) Pentapetides and a method of preparing them
Morimoto et al. [39] Biosynthesis of cytochrome c and its posttranslational transfer into mitochondria
FR2429224A1 (fr) Procede pour isoler l'acide chenodesoxycholique de la bile de porc et pour le purifier et son application a la dissolution de calculs biliaires in vivo
KITAGAWA et al. Alternative Synthesis of Substance P

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH

MA Patent expired